Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GF2R
|
|||
| Drug Name |
KN035
|
|||
| Synonyms |
Envafolimab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Pleomorphic sarcoma [ICD-11: 2B54; ICD-9: 171] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 2 | [2] | ||
| Advanced malignancy [ICD-11: 2A00-2F9Z] | Phase 1 | [3] | ||
| Company |
TRACON Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death 1 ligand 1 (PD-L1) | Target Info | . | [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Reactome | PD-1 signaling | |||
| WikiPathways | Costimulation by the CD28 family | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04480502) ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04891198) ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 3 | Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.